Testing Whether High Dose Chemotherapy and Infusion of the Patients' Own Stem Cells Improves Survival in Patients With Peripheral T-cell Lymphoma Who Achieved a Complete Response at the End of the Initial Chemotherapy

Recruiting

Phase 3

High Dose Chemotherapy & Autologous Stem CellsTesting Whether High Dose Chemotherapy and Infusion of the Patients' Own Stem Cells Improves Survival in Patients With Peripheral T-cell Lymphoma Who Achieved a Complete Response at the End of the Initial Chemotherapy

Sponsor:

Eastern Cooperative Oncology Group

Code:

NCT06724237

Conditions

Anaplastic Large Cell Lymphoma, ALK-Negative

Follicular Helper T-Cell Lymphoma

Follicular Helper T-Cell Lymphoma, Angioimmunoblastic-Type

Peripheral T-Cell Lymphoma, Not Otherwise Specified

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

Autologous Hematopoietic Stem Cell Transplantation

Best Practice

Biospecimen Collection

Bone Marrow Aspiration

Bone Marrow Biopsy

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-05-20. This information was provided to ClinicalTrials.gov by Eastern Cooperative Oncology Group on 2026-05-15.